<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-5173</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Medicina Geral e Familiar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Med Geral Fam]]></abbrev-journal-title>
<issn>2182-5173</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa de Medicina Geral e Familiar]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-51732012000200008</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Uma causa rara de hipertensão arterial secundária]]></article-title>
<article-title xml:lang="en"><![CDATA[A rare cause of secondary arterial hypertension]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pessoa]]></surname>
<given-names><![CDATA[Marta]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sérgio]]></surname>
<given-names><![CDATA[Carla]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,USF Buarcos  ]]></institution>
<addr-line><![CDATA[Buarcos ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2012</year>
</pub-date>
<volume>28</volume>
<numero>2</numero>
<fpage>126</fpage>
<lpage>133</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-51732012000200008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-51732012000200008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-51732012000200008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Introdução: A Polineuropatia Amilóide Familiar (PAF) tipo 1, mais conhecida por «Doença dos Pezinhos», é a forma hereditária mais comum de amiloidose, causada pela acumulação de uma proteína mutante (transtirretina). Trata-se duma doença rara e de difícil diagnóstico, principalmente quando não há antecedentes familiares. Descrição do caso: Mulher de 60 anos de idade, com antecedentes pessoais de hipotiroidismo, dislipidémia, hiperuricémia, perturbação mista ansioso-depressiva, doença venosa dos membros inferiores e Hipertensão arterial (HTA). Em Junho de 2009 foi observada pela primeira vez pela actual médica de família, trazendo resultados de exames laboratoriais que revelavam proteinúria, em sumária de urina. Após pedido de microalbuminúria e cintigrama renal que revelaram insuficiência renal crónica (IRC), foi referenciada para a consulta de Nefrologia do Centro Hospitalar de Coimbra (CHC), onde iniciou estudo etiológico. Em Agosto de 2010 foi internada no Serviço de Nefrologia do CHC com o diagnóstico de insuficiência renal rapidamente progressiva com proteinúria nefrótica. Realizou biópsia renal cujo resultado revelou amiloidose familiar tipo português (ATTR). Foi orientada para a consulta de Paramiloidose do Hospital Geral de Santo António que actualmente frequenta. Comentário: A discussão deste caso clínico pretende alertar para a importância da realização de uma investigação adequada de um doente com hipertensão arterial. Esta pode revelar factores etiológicos que, mesmo sendo raros e tendo um contexto epidemiológico atípico, devem sempre ser incluídos no processo de raciocínio clínico e diagnóstico diferencial.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Introduction: Familial amyloid polyneuropathy (FAP) type 1, better known in Portugal as “Doença dos Pezinhos”, is a hereditary form of amyloidosis caused by the accumulation of a mutant protein (transthyretin). It is a rare disease which may be difficult to diagnose when there is no previous family history of the condition. Case description: This report describes the case of a 60-year-old Caucasian woman with a history of hypothyroidism, dyslipidemia, hyperuricemia, mixed anxiety and depressive disorder, chronic venous disease of the legs and hypertension. In June 2009, she was seen for the first time by her new family doctor, with laboratory results that showed proteinuria. A 24-hour urine collection for microalbuminuria and a renal scan were obtained. A diagnosis of chronic renal failure was made. The patient was referred for a nephrology consultation in a central hospital where additional tests were done to determine the cause of her illness. In August 2010, she was hospitalised in the nephrology unit with rapidly progressive renal failure with nephrotic proteinuria. A renal biopsy showed familial amyloidosis, Portuguese type (ATTR). She was then referred to the familial amyloid polyneuropathy clinic in another hospital. Comment: This case report shows the importance of adequate investigation in a patient with arterial hypertension. It also shows how rare causes may be considered in common clinical syndromes.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Polineuropatia Amilóide Familiar]]></kwd>
<kwd lng="pt"><![CDATA[Hipertensão arterial]]></kwd>
<kwd lng="pt"><![CDATA[Nefropatia]]></kwd>
<kwd lng="en"><![CDATA[Amyloid Neuropathies]]></kwd>
<kwd lng="en"><![CDATA[Familial]]></kwd>
<kwd lng="en"><![CDATA[Hypertension]]></kwd>
<kwd lng="en"><![CDATA[Kidney Diseases]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><b>RELATOS DE CASOS</b></p>     <p><font size="4"><b>Uma causa rara de hipertens&#227;o arterial     secund&#225;ria</b></font></p>     <p><font size="3"><b>A rare cause of secondary arterial hypertension</b></font></p>       <p><b>Marta Pessoa,* Carla S&#233;rgio**</b></p>       <p>*Interna     Complementar Medicina Geral e Familiar, USF Buarcos.</p>       <p>**Assistente     de Medicina Geral e Familiar, USF Buarcos.</p>       <p><a href="#c0">Endere&ccedil;o para correspond&ecirc;ncia</a> | <a href="#c0">Direcci&oacute;n para correspondencia</a> | <a href="#c0">Correspondence</a><a name="topc0"></a></p> <hr/>    <p>&nbsp;</p>      <p><b>RESUMO</b></p>       <p><b>Introdu&#231;&#227;o:</b> A Polineuropatia Amil&#243;ide     Familiar (PAF) tipo 1, mais conhecida por &#171;Doen&#231;a dos Pezinhos&#187;, &#233; a forma     heredit&#225;ria mais comum de amiloidose, causada pela acumula&#231;&#227;o de uma prote&#237;na     mutante (transtirretina). Trata-se duma doen&#231;a rara e de dif&#237;cil diagn&#243;stico,     principalmente quando n&#227;o h&#225; antecedentes familiares.</p>       ]]></body>
<body><![CDATA[<p><b>Descri&#231;&#227;o do caso:</b> Mulher de 60 anos de     idade, com antecedentes pessoais de hipotiroidismo, dislipid&#233;mia,     hiperuric&#233;mia, perturba&#231;&#227;o mista ansioso-depressiva, doen&#231;a venosa dos membros     inferiores e Hipertens&#227;o arterial (HTA). Em Junho de 2009 foi observada pela     primeira vez pela actual m&#233;dica de fam&#237;lia, trazendo resultados de exames     laboratoriais que revelavam protein&#250;ria, em sum&#225;ria de urina. Ap&#243;s pedido de     microalbumin&#250;ria e cintigrama renal que revelaram insufici&#234;ncia renal cr&#243;nica     (IRC), foi referenciada para a consulta de Nefrologia do Centro Hospitalar de     Coimbra (CHC), onde iniciou estudo etiol&#243;gico. Em Agosto de 2010 foi internada     no Servi&#231;o de Nefrologia do CHC com o diagn&#243;stico de insufici&#234;ncia renal     rapidamente progressiva com protein&#250;ria nefr&#243;tica. Realizou bi&#243;psia renal cujo     resultado revelou amiloidose familiar tipo portugu&#234;s (ATTR). Foi orientada para     a consulta de Paramiloidose do Hospital Geral de Santo Ant&#243;nio que actualmente     frequenta.</p>       <p><b>Coment&#225;rio:</b> A discuss&#227;o deste caso     cl&#237;nico pretende alertar para a import&#226;ncia da realiza&#231;&#227;o de uma investiga&#231;&#227;o     adequada de um doente com hipertens&#227;o arterial. Esta pode revelar factores     etiol&#243;gicos que, mesmo sendo raros e tendo um contexto epidemiol&#243;gico at&#237;pico,     devem sempre ser inclu&#237;dos no processo de racioc&#237;nio cl&#237;nico e diagn&#243;stico     diferencial.</p>       <p><b>Palavras-chave:</b> Polineuropatia Amil&#243;ide     Familiar; Hipertens&#227;o arterial; Nefropatia.</p>   <hr/>       <p><b>ABSTRACT</b></p>        <p><b>Introduction:</b> Familial amyloid     polyneuropathy (FAP) type 1, better known in Portugal as &#8220;Doen&#231;a dos Pezinhos&#8221;,     is a hereditary form of amyloidosis caused by the accumulation of a mutant     protein (transthyretin). It is a rare disease which may be difficult to     diagnose when there is no previous family history of the condition.</p>       <p><b>Case description:</b> This report describes     the case of a 60-year-old Caucasian woman with a history of hypothyroidism,     dyslipidemia, hyperuricemia, mixed anxiety and depressive disorder, chronic     venous disease of the legs and hypertension. In June 2009, she was seen for the     first time by her new family doctor, with laboratory results that showed     proteinuria. A 24-hour urine collection for microalbuminuria and a renal scan     were obtained. A diagnosis of chronic renal failure was made. The patient was     referred for a nephrology consultation in a central hospital where additional     tests were done to determine the cause of her illness. In August 2010, she was     hospitalised in the nephrology unit with rapidly progressive renal failure with     nephrotic proteinuria. A renal biopsy showed familial amyloidosis, Portuguese     type (ATTR). She was then referred to the familial amyloid polyneuropathy     clinic in another hospital.</p>       <p><b>Comment:</b> This case report shows the importance     of adequate investigation in a patient with arterial hypertension. It also     shows how rare causes may be considered in common clinical syndromes.</p>       <p><b>Key words:</b> Amyloid Neuropathies;     Familial; Hypertension; Kidney Diseases.</p>  <hr/>       <p><b>INTRODU&#199;&#195;O</b></p>       <p>A HTA &#233; de     causa idiop&#225;tica em mais de 90% dos casos, mas deve-se pensar em causas     secund&#225;rias perante um utente cumpridor da medica&#231;&#227;o e das medidas     higieno-diet&#233;ticas com valores de tens&#227;o arterial (TA) de dif&#237;cil controlo ou     com les&#227;o de &#243;rg&#227;o alvo progressiva apesar do controlo da TA.</p>       ]]></body>
<body><![CDATA[<p>Apresenta-se     o caso duma mulher com HTA e protein&#250;ria nefr&#243;tica rapidamente progressiva, o     que fez suspeitar duma causa renal confirmada por bi&#243;psia que revelou PAF.</p>       <p>A     paramiloidose, amiloidose familiar tipo 1 (portugu&#234;s) ou PAF foi descrita pela     primeira vez em Portugal, em 1952, por Corino de Andrade.<sup>1,2</sup> Sabe-se     que, em 2003, existiam mais de 1500 pacientes portadores desta doen&#231;a em     Portugal.<sup>3</sup></p>       <p>A PAF tipo 1     &#233; considerada uma doen&#231;a de transmiss&#227;o autoss&#243;mica dominante, end&#233;mica em     Portugal e de elevada penetr&#226;ncia (mais de 90% dos indiv&#237;duos portadores da     muta&#231;&#227;o TTR V30M desenvolvem sintomatologia na idade adulta).<sup>1,3,4</sup> O     pico de incid&#234;ncia da doen&#231;a est&#225; compreendido entre a terceira e a quarta     d&#233;cadas de vida.<sup>1,11</sup> &#201; uma doen&#231;a progressiva, altamente     incapacitante e fatal na maioria dos casos, ocorrendo a morte ao fim de uma     m&#233;dia de 11 anos de doen&#231;a.<sup>4-6</sup></p>       <p>Na maioria     das situa&#231;&#245;es, os doentes apresentam sintomatologia inespec&#237;fica (cansa&#231;o f&#225;cil     e perda de peso), sendo o diagn&#243;stico tardio, quando n&#227;o h&#225; hist&#243;ria familiar     pr&#233;via. Como a pr&#243;pria designa&#231;&#227;o indica, a PAF envolve, mais frequentemente,     os nervos perif&#233;ricos, manifestando-se por neuropatia sensorio-motora e     auton&#243;mica.<sup>3,7-8</sup> No entanto, adopta, na maioria dos casos,     propor&#231;&#245;es de doen&#231;a sist&#233;mica.</p>       <p>Actualmente     n&#227;o existe tratamento m&#233;dico espec&#237;fico dispon&#237;vel, capaz de inverter o     processo de forma&#231;&#227;o de subst&#226;ncia amil&#243;ide TTR.<sup>1</sup> Em termos     cir&#250;rgicos, o transplante hep&#225;tico &#233; considerado o &#250;nico tratamento eficaz na     PAF.<sup>1,3,6,8-10</sup> Idealmente, o transplante hep&#225;tico dever&#225; ser     realizado num est&#225;dio precoce da doen&#231;a, ou seja, antes da instala&#231;&#227;o de     qualquer disfun&#231;&#227;o neurol&#243;gica e, preferencialmente, no primeiro ano ap&#243;s o     in&#237;cio de sintomatologia.<sup>1-2,4,7,12</sup></p>       <p>A detec&#231;&#227;o     precoce da doen&#231;a permite o tratamento atrasando a sua evolu&#231;&#227;o natural, melhorando     a sintomatologia, qualidade de vida e sobrevida.</p>       <p><b>DESCRI&#199;&#195;O DO CASO</b></p>       <p><b>Identifica&#231;&#227;o e caracteriza&#231;&#227;o familiar</b></p>       <p>M.T.P.R.M.,     sexo feminino, de 60 anos de idade, ra&#231;a caucasiana, divorciada, escritur&#225;ria,     natural de Leiria e residente na Figueira da Foz, com o quarto ano de     escolaridade.</p>       <p>Vive     sozinha, mas tem apoio do filho com quem tem uma rela&#231;&#227;o excelente (<a href="/img/revistas/rpmgf/v28n2/28n2a08f1.jpg" target="_blank">Figura 1</a> e <a href="#f2">2</a>). Trata-se duma fam&#237;lia unit&#225;ria, de classe m&#233;dia.</p>       
]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p align="center"><a href="/img/revistas/rpmgf/v28n2/28n2a08f1.jpg" target="_blank"><img src="/img/revistas/rpmgf/v28n2/28n2a08f1.jpg" width="300" height="167"/><br />(clique para ampliar ! click to enlarge)</a></p>       
<p>&nbsp;</p>           <p align="center"><img src="/img/revistas/rpmgf/v28n2/28n2a08f2.jpg"/><a name="f2"></a></p>       
<p>&nbsp;</p>       <p>O genograma     apresenta-nos os problemas familiares mais relevantes, dos quais se destaca a     m&#227;e que faleceu em sequ&#234;ncia de IRC de prov&#225;vel etiologia hipertensiva, assim     como a hist&#243;ria oncol&#243;gica (neoplasia colo-rectal) presente nas tr&#234;s tias   maternas (<a href="/img/revistas/rpmgf/v28n2/28n2a08f1.jpg" target="_blank">Figura 1</a>).</p>       
<p><b>Problemas de sa&#250;de activos e medica&#231;&#227;o     cr&#243;nica</b></p>       <p>&#8226; Hipotiroidismo     (desde 1998),</p>       <p>&#8226; Dislipid&#233;mia     (desde 2003),</p>       <p>&#8226; Perturba&#231;&#227;o     mista ansioso-depressiva (desde 1999),</p>       ]]></body>
<body><![CDATA[<p>&#8226; Doen&#231;a     venosa dos membros inferiores (desde 2009),</p>       <p>&#8226; Hipertens&#227;o     arterial (desde 2011).</p>       <p>Faz a     seguinte medica&#231;&#227;o cr&#243;nica: levotiroxina </p>       <p>0,25 mg 1id,     losartan 50 mg 2id, amlodipina 5 mg 1id, furosemida 40 mg 3id, sinvastatina 20     mg 1id e alprazolam 0,25 mg 2id.</p>       <p><b>H&#225;bitos</b></p>       <p>Alimenta&#231;&#227;o     variada e equilibrada, negando h&#225;bitos alco&#243;licos, tab&#225;gicos ou consumo de     drogas. N&#227;o faz actividade f&#237;sica regular. Tem o plano vacinal actualizado e     nega ter qualquer tipo de alergias. Epis&#243;dios espor&#225;dicos de ins&#243;nia inicial     controlados com medica&#231;&#227;o ansiol&#237;tica.</p>       <p><b>Antecedentes Ginecol&#243;gicos e Obst&#233;tricos</b></p>       <p>Menarca aos     12 anos de idade com ciclos menstruais regulares (catam&#233;nios de cinco dias e     interl&#250;nios de 28 dias). Histerectomia total com anexectomia subtotal (com     remo&#231;&#227;o do ov&#225;rio direito) aos 35 anos de idade, por miomatose uterina. Gesta I     Para I, gravidez sem intercorr&#234;ncias com parto eut&#243;cico, em 1971.</p>       <p><b>Hist&#243;ria da doen&#231;a actual</b></p>       <p><b>Consulta 23.06.2009</b></p>       ]]></body>
<body><![CDATA[<p>A utente     comparece a consulta programada, a primeira com a sua actual m&#233;dica de fam&#237;lia     (MF), trazendo resultados de exames laboratoriais e imagiol&#243;gicos solicitados     pela MF anterior. Ao exame objectivo apresenta IMC de 23,4 kg/m<sup>2</sup>,     valor de tens&#227;o arterial de 160/80 mmHg, edemas dos membros inferiores, sopro     sist&#243;lico &#224; ausculta&#231;&#227;o card&#237;aca, ausculta&#231;&#227;o pulmonar sem altera&#231;&#245;es. As     an&#225;lises sangu&#237;neas demonstram     um valor de ureia elevado, com um valor de creatinina normal, apresentando uma     sum&#225;ria de urina tipo II com protein&#250;ria (<a href="#q1">Quadro I</a>). A ecografia renal     evidenciava &#171;quisto simples no p&#243;lo inferior do rim esquerdo com cerca de 4 cm,     sem outras altera&#231;&#245;es&#187;.</p>     <p>&nbsp;</p>    <p align="center"><a name="q1"></a><img src="/img/revistas/rpmgf/v28n2/28n2a08q1.jpg"/></p>    
<p>&nbsp;</p>        <p>Foram     solicitadas novas an&#225;lises de sangue e urina com microalbumin&#250;ria das 24 horas,     electrocardiograma (ECG) e ecocardiograma. Foram aconselhadas medidas     higieno-diet&#233;ticas com manuten&#231;&#227;o da medica&#231;&#227;o j&#225; prescrita anteriormente pela     sua &#250;ltima m&#233;dica de fam&#237;lia (furosemida 40 mg; losartan com hidroclorotiazida     50 mg/12,5 mg e rosuvastatina 10 mg), assim como vigil&#226;ncia dos valores de     tens&#227;o arterial em ambulat&#243;rio.</p>       <p><b>Consulta 27.07.2009</b></p>       <p>A utente vem     novamente a consulta programada com a sua MF trazendo resultados de exames     complementares solicitados. Os valores de tens&#227;o arterial em ambulat&#243;rio     mantiveram-se sempre acima de 140/90 mmHg. Ao exame objectivo apresenta tens&#227;o     arterial de 160/90 mmHg, com diminui&#231;&#227;o dos edemas dos membros inferiores. As     an&#225;lises demonstram uma eleva&#231;&#227;o do valor da ureia e microalbumin&#250;ria de 823     mg/24h (protein&#250;ria nefr&#243;tica). As provas de fun&#231;&#227;o tiroideia revelaram um     hipotiroidismo (<a href="#q1">Quadro I</a>). O ionograma, n&#237;veis de c&#225;lcio e f&#243;sforo,     proteinograma electrofor&#233;tico e ECG n&#227;o apresentavam altera&#231;&#245;es.</p>         <p>O     ecocardiograma demonstrou &#171;insufici&#234;ncia mitral e tric&#250;spide muito ligeira&#187;. &#201;     feito ajuste da medica&#231;&#227;o hormonal tiroideia, solicitado ecografia da tir&#243;ide e     cintigrama renal, tendo sido pedida consulta de Nefrologia do CHC. Foi feito     refor&#231;o das medidas higieno-diet&#233;ticas.</p>       <p><b>Consulta 07.09.2009</b></p>       <p>A utente     apresenta-se em consulta programada com resultados dos exames imagiol&#243;gicos     pedidos na consulta anterior. Ao exame objectivo, o valor de tens&#227;o     arterial avaliada &#233; de 130/75 mmHg e sem edemas dos membros inferiores. O     cintigrama renal revela &#171;rins de dimens&#245;es diminu&#237;das com alguma estase     intraparenquimatosa; bilateralmente com diminui&#231;&#227;o da elimina&#231;&#227;o do f&#225;rmaco&#187;. A     ecografia da tir&#243;ide demonstra &#171;n&#243;dulo hipoecog&#233;nico de cerca de 4 mm com &#225;rea     calcificada&#187;. Nesta consulta &#233; feito o diagn&#243;stico de IRC sendo solicitadas     novas an&#225;lises sangu&#237;neas enquanto a utente aguardava a consulta de Nefrologia.</p>       ]]></body>
<body><![CDATA[<p><b>Consulta 04.01.2010</b></p>       <p>Nesta     consulta programada, a utente vem informar a sua MF que j&#225; foi &#224; consulta de     Nefrologia do CHC e que ir&#225; iniciar estudo etiol&#243;gico da IRC. Foi mantida a     medica&#231;&#227;o que j&#225; fazia, com aumento da dose da furosemida, altera&#231;&#227;o do     losartan com hidroclorotiazida 50 mg/12,5 mg para losartan 50 mg 2id e     amlodipina 5 mg 1id e da rosuvastatina 10 mg para sinvastatina 20 mg id. Foi     prescrito &#225;cido f&#243;lico, vitaminas do complexo B e calcitriol. Novamente a     utente traz consigo resultados das an&#225;lises solicitadas que demonstram um valor     de ureia e creatinina elevados, bem como uma sum&#225;ria de urina tipo II com     protein&#250;ria de 100 mg/dL (<a href="#q1">Quadro I</a>).</p>       <p>Ao exame     objectivo, apresenta uma tens&#227;o arterial de 135/80 mmHg. A pedido da consulta     hospitalar de Nefrologia, s&#227;o solicitadas ecografias abdominal, renal e     vesical.</p>       <p><b>Consulta 13.09.2010</b></p>       <p>A utente     comparece, novamente, em consulta programada informando a sua MF que recorreu,     no m&#234;s anterior, ao Servi&#231;o de Urg&#234;ncia (SU) do Hospital Distrital da Figueira     da Foz por queixas de dis&#250;ria e polaqui&#250;ria, tendo-lhe sido diagnosticado uma     infec&#231;&#227;o do tracto urin&#225;rio por <i>Escherichia     coli,</i> com agravamento da fun&#231;&#227;o renal. A utente &#233; portadora de an&#225;lises     efectuadas neste epis&#243;dio de urg&#234;ncia. Nesta mesma altura, a utente inicia     queixas de na&#250;seas frequentes. Ao exame objectivo, evidenciam-se edemas     ligeiros dos membros inferiores e um valor de tens&#227;o arterial de 150/85 mmHg.     As an&#225;lises do SU demonstram um agravamento dos valores de fun&#231;&#227;o renal sem, no     entanto, existirem desequil&#237;brios hidro-electrol&#237;ticos (<a href="#q1">Quadro I</a>).</p>       <p>S&#227;o     solicitadas novas an&#225;lises sangu&#237;neas para esta levar &#224; consulta de Nefrologia     do CHC.</p>       <p><b>Consulta 29.09.2010</b></p>       <p>Cerca de 15     dias depois, a utente vem novamente a uma consulta, trazendo uma carta de alta     do Servi&#231;o de Nefrologia do CHC, onde esteve internada cerca de 10 dias. A     utente recorreu ao Servi&#231;o de Urg&#234;ncia daquele hospital por agravamento do     quadro de na&#250;seas. Foi-lhe diagnosticada insufici&#234;ncia renal rapidamente     progressiva, tendo realizado bi&#243;psia renal, da qual aguarda resultado     histol&#243;gico. Foram adicionados &#224; medica&#231;&#227;o cr&#243;nica carbonato de c&#225;lcio e     eritropoetina.</p>       <p>Os valores     anal&#237;ticos referidos na carta de alta evidenciavam anemia normocr&#243;mica     normoc&#237;tica com agravamento dos valores de fun&#231;&#227;o renal, urina das 24 horas com     4160 mg de protein&#250;ria e clearance de creatinina de 25,5 ml/min (<a href="#q1">Quadro I</a>).     Realizou estudo da fun&#231;&#227;o hep&#225;tica e tiroideia, serologias v&#237;ricas e estudo     auto-imune, que se revelaram dentro da normalidade.</p>       <p>Ao exame     objectivo, foi avaliado um valor de tens&#227;o arterial de 145/80 mmHg.</p>       ]]></body>
<body><![CDATA[<p>Foi     classificada a insufici&#234;ncia renal cr&#243;nica em est&#225;dio quatro, sendo solicitadas     novas an&#225;lises sangu&#237;neas para a pr&#243;xima consulta de especialidade.</p>       <p>A utente     estava muito ansiosa e apreensiva com o poss&#237;vel resultado da bi&#243;psia, pelo que     foram esclarecidas todas as d&#250;vidas apresentadas, dando espa&#231;o ao di&#225;logo,     tendo-se mostrado disponibilidade para a utente regressar ou contactar pelo     telefone sempre que necess&#225;rio.</p>       <p><b>Consulta 11.10.2010</b></p>       <p>Em consulta     n&#227;o presencial, s&#227;o registados os valores das an&#225;lises solicitadas que     revelavam um agravamento da anemia normocr&#243;mica normoc&#237;tica e da fun&#231;&#227;o renal,     mantendo-se os valores de c&#225;lcio e f&#243;sforo dentro da normalidade (<a href="#q1">Quadro I</a>). A     utente foi informada destes resultados telefonicamente, tendo sido solicitadas     novas an&#225;lises sangu&#237;neas.</p>       <p><b>Consulta 04.01.2011</b></p>       <p>A utente     comparece &#224; consulta programada com a sua MF, trazendo consigo o resultado da     bi&#243;psia renal efectuada durante o internamento em Setembro de 2010. A bi&#243;psia     renal revela presen&#231;a de subst&#226;ncia amil&#243;ide familiar tipo portugu&#234;s &#8211;     TTR positiva. &#201; assim feito o diagn&#243;stico de PAF.</p>       <p>&#201; feita     referencia&#231;&#227;o da utente para a consulta de PAF realizada no Hospital de Santo     Ant&#243;nio, que actualmente frequenta e onde j&#225; lhe foi proposto transplante duplo     de f&#237;gado e rim, para o qual se encontra em lista de espera. O filho da utente     foi igualmente chamado a esta consulta espec&#237;fica onde j&#225; iniciou investiga&#231;&#227;o     complementar.</p>       <p>Nesta     consulta, a utente apresenta-se muito ansiosa, apreensiva com o diagn&#243;stico e     preocupada com o futuro, nomeadamente com a hip&#243;tese do filho poder ter a mesma     doen&#231;a. Foi explicado &#224; utente as principais caracter&#237;sticas da doen&#231;a, sua     monitoriza&#231;&#227;o, poss&#237;veis tratamentos e progn&#243;stico. Esta, por j&#225; ter recolhido     muita informa&#231;&#227;o atrav&#233;s da internet e por contacto com utentes com PAF, tem     uma perspectiva pouco animadora do futuro que se avizinha.</p>       <p><b>COMENT&#193;RIO</b></p>       <p>No caso da     utente cujo caso cl&#237;nico &#233; aqui descrito, a constata&#231;&#227;o de valores de tens&#227;o     arterial descontrolados, associados a resultados de fun&#231;&#227;o renal alterados e     com agravamento progressivo, fizeram colocar a hip&#243;tese de se estar perante um     caso de hipertens&#227;o secund&#225;ria e o estudo etiol&#243;gico da hipertens&#227;o arterial     foi, desde in&#237;cio, dirigido para uma prov&#225;vel causa renal. O valor de     microalbumin&#250;ria de 823 mg/dL (protein&#250;ria nefr&#243;tica) fez desde logo levantar a     suspeita (<a href="#q1">Quadro I</a>) e o cintigrama renal confirmou estar-se em presen&#231;a de uma     IRC. &#201; feita a referencia&#231;&#227;o da utente para os Cuidados de Sa&#250;de Secund&#225;rios     para diagn&#243;stico etiol&#243;gico.</p>       ]]></body>
<body><![CDATA[<p>O     agravamento da fun&#231;&#227;o renal, despoletado pela infec&#231;&#227;o do tracto urin&#225;rio e o     in&#237;cio do quadro de na&#250;seas, desencadearam o internamento no Servi&#231;o de     Nefrologia do CHC. O estudo da fun&#231;&#227;o hep&#225;tica e tiroideia, serologias v&#237;ricas     e estudo autoimune excluiu prov&#225;veis causas de IRC. A bi&#243;psia renal foi     necess&#225;ria para identificar a prov&#225;vel causa da IRC e o estudo histol&#243;gico     detectou a presen&#231;a de subst&#226;ncia amil&#243;ide do tipo portugu&#234;s &#8211; TTR     positiva, fazendo o diagn&#243;stico de PAF TTR positiva.</p>       <p>Existem     condi&#231;&#245;es que na literatura cient&#237;fica consultada s&#227;o apresentadas como     pontos-chave da PAF e que, neste caso cl&#237;nico, se mostram desfavor&#225;veis a este     diagn&#243;stico. S&#227;o exemplo disso a idade do in&#237;cio de sintomatologia, a d&#250;vida     sobre a exist&#234;ncia de antecedentes familiares, a aus&#234;ncia de queixas     demonstrativas de polineuropatia sens&#243;rio-motora como sintomatologia inicial,     assim como de sintomatologia t&#237;pica de disfun&#231;&#227;o auton&#243;mica (altera&#231;&#227;o dos     h&#225;bitos intestinais e do esvaziamento g&#225;strico, hipotens&#227;o postural ou queixas     genito-urin&#225;rias).<sup>2</sup></p>       <p>Relativamente     &#224; idade de in&#237;cio da sintomatologia, a PAF &#233; uma patologia que se manifesta,     com maior frequ&#234;ncia, entre a terceira e a quarta d&#233;cadas de vida. No entanto,     existem alguns casos de in&#237;cio tardio da doen&#231;a descritos na literatura     cient&#237;fica.<sup>13</sup></p>       <p>Um dos     pontos a favor do diagn&#243;stico de PAF num indiv&#237;duo &#233; a hist&#243;ria familiar. No     entanto, em 13% dos casos podem n&#227;o existir antecedentes familiares.13 Neste     caso cl&#237;nico a utente apenas soube informar que a sua m&#227;e tamb&#233;m era hipertensa     e que faleceu j&#225; a realizar hemodi&#225;lise, situa&#231;&#227;o que leva a suspeitar que,     provavelmente, esta tamb&#233;m sofreria de PAF. O &#250;nico familiar que actualmente     demonstrou interesse em realizar investiga&#231;&#227;o complementar foi o filho da     utente, que j&#225; foi consultado no Hospital de Santo Ant&#243;nio. O estudo que     realizou foi negativo, n&#227;o sendo, portanto, portador desta muta&#231;&#227;o g&#233;nica e da     doen&#231;a da m&#227;e.</p>       <p>Outro dos     pontos favor&#225;veis ao diagn&#243;stico de PAF &#233; a polineuropatia sensorio-motora que     n&#227;o foi motivo de queixa por parte da utente (nomeadamente parestesias dos     membros inferiores). No entanto, segundo informa&#231;&#245;es da equipa de enfermagem, a     utente recorreu recentemente aos cuidados desta para tratamento de escoria&#231;&#245;es     e lacera&#231;&#245;es indolores nos p&#233;s, o que permite concluir que j&#225; poder&#225; haver     algum grau de neuropatia amil&#243;ide.</p>       <p>A PAF &#233; uma     doen&#231;a que geralmente adquire propor&#231;&#245;es de doen&#231;a sist&#233;mica, condicionando,     com bastante frequ&#234;ncia, a qualidade de vida dos doentes. A equipa de sa&#250;de     (m&#233;dica e enfermeira de fam&#237;lia) tem tido a preocupa&#231;&#227;o de, al&#233;m de     proporcionar os devidos cuidados de sa&#250;de, dar o apoio psicol&#243;gico que esta     utente necessita. Apesar de se tratar de uma fam&#237;lia unit&#225;ria, a utente sempre     referiu ter grande apoio psicol&#243;gico, funcional e econ&#243;mico por parte de     familiares pr&#243;ximos e amigos. Essa situa&#231;&#227;o foi avaliada e confirmada atrav&#233;s     de alguns m&#233;todos de avalia&#231;&#227;o familiar (<a href="/img/revistas/rpmgf/v28n2/28n2a08f1.jpg" target="_blank">Figura 1</a> e <a href="#f2">2</a>).</p>       
<p>O papel do     MF perante patologias menos frequentes, como &#233; o caso da PAF, n&#227;o &#233; de menor     import&#226;ncia. Apesar da maioria destes doentes, sen&#227;o a totalidade deles, ter     seguimento em consultas peri&#243;dicas nos Cuidados de Sa&#250;de Secund&#225;rios e     Terci&#225;rios, &#233; ao MF que cabe acompanh&#225;-los em ambulat&#243;rio, durante toda a vida.     A articula&#231;&#227;o entre Cuidados de Sa&#250;de Prim&#225;rios e Secund&#225;rios/Terci&#225;rios &#233; de     extrema import&#226;ncia, principalmente nos doentes cr&#243;nicos, portadores de doen&#231;a     sist&#233;mica e incapacitante. &#201; fundamental a monitoriza&#231;&#227;o cont&#237;nua e a preven&#231;&#227;o     de les&#245;es secund&#225;rias de &#243;rg&#227;os alvo, devendo o MF receber informa&#231;&#227;o de     retorno por parte dos cuidados hospitalares, de forma a tamb&#233;m poder     participar, de forma activa, nesta vigil&#226;ncia peri&#243;dica. Igualmente, &#233; tamb&#233;m     no MF que estes doentes encontram o apoio psicol&#243;gico e conforto emocional de     que tanto necessitam, de modo a se sentirem motivados para enfrentarem,     diariamente, as limita&#231;&#245;es e as complica&#231;&#245;es impostas pela doen&#231;a.</p>       <p>Em termos de     vigil&#226;ncia peri&#243;dica, o MF deve ter em aten&#231;&#227;o quais os principais     sistemas/&#243;rg&#227;os alvo que a PAF poder&#225; atingir e redobrar a sua vigil&#226;ncia sobre     estes (<a href="#q2">Quadro II</a>):</p>     <p>&nbsp;</p>         <p align="center"><a name="q2"></a><img src="/img/revistas/rpmgf/v28n2/28n2a08q2.jpg"/></p>           
]]></body>
<body><![CDATA[<p>&nbsp;</p>       <p>&#8226; Sistema     cardiovascular: a vigil&#226;ncia deve ser realizada com ecocardiograma.<sup>14</sup> Igualmente, poder&#225; ser oportuna a realiza&#231;&#227;o peri&#243;dica de ECG de 12 deriva&#231;&#245;es     e/ou cintigrama de perfus&#227;o de mioc&#225;rdio.<sup>14</sup></p>       <p>&#8226; Sistema     neurol&#243;gico: a monitoriza&#231;&#227;o deve incluir um exame neurol&#243;gico sum&#225;rio, com     especial aten&#231;&#227;o ao exame do p&#233;, testando os v&#225;rios tipos de sensibilidade     (&#225;lgica, vibrat&#243;ria e proprioceptiva).<sup>12,14-16</sup> O MF deve igualmente     questionar o doente sobre sintomatologia reveladora de disfun&#231;&#227;o auton&#243;mica     (altera&#231;&#227;o dos h&#225;bitos intestinais e do esvaziamento g&#225;strico, hipotens&#227;o postural,     reten&#231;&#227;o ou incontin&#234;ncia urin&#225;rias e disfun&#231;&#227;o er&#233;ctil).<sup>2,12</sup></p>       <p>&#8226; Olhos: a     preven&#231;&#227;o prim&#225;ria do aparecimento de opacidades v&#237;treas por deposi&#231;&#227;o de     subst&#226;ncia amil&#243;ide deve ser efectuada atrav&#233;s de consulta de Oftalmologia     peri&#243;dica.<sup>14</sup></p>       <p>&#8226; Sistema renal:     a vigil&#226;ncia da fun&#231;&#227;o renal dever&#225; incluir monitoriza&#231;&#227;o peri&#243;dica dos valores     de creatinina e ureia.<sup>8,14</sup> A detec&#231;&#227;o de microalbumin&#250;ria representa     um est&#225;dio precoce de nefropatia amil&#243;ide e geralmente precede a instala&#231;&#227;o de     neuropatia.<sup>6-7,17</sup></p>       <p>A instala&#231;&#227;o     de insufici&#234;ncia renal cr&#243;nica origina anemia por defici&#234;ncia de eritropoetina,     situa&#231;&#227;o muito frequente nos est&#225;dios tardios da doen&#231;a (presente em 25% dos     pacientes com PAF tipo 1 ap&#243;s uma m&#233;dia de 9 anos de doen&#231;a) e cuja correc&#231;&#227;o     dever&#225; ser feita atrav&#233;s da administra&#231;&#227;o da variante recombinante humana desta     hormona.<sup>5,14,17-20</sup></p>       <p>O     transplante hep&#225;tico ortot&#243;pico (THO) &#233; a &#250;nica op&#231;&#227;o terap&#234;utica actual com     resultados favor&#225;veis para os doentes com PAF. &#201; realizado amplamente como     terapia g&#233;nica cir&#250;rgica (95% da prote&#237;na TTR mutante &#233; produzida no f&#237;gado).<sup>21</sup></p>       <p>Em termos de     sintomatologia, o THO demonstra estabiliza&#231;&#227;o e alguma regress&#227;o da neuropatia     auton&#243;mica, melhoria da neuropatia perif&#233;rica e deteriora&#231;&#227;o mais lenta da     fun&#231;&#227;o renal, relativamente aos doentes que n&#227;o realizaram THO.<sup>6,8</sup></p>       <p>Caso a     fun&#231;&#227;o renal esteja gravemente deteriorada, como &#233; o caso da utente descrita     neste caso cl&#237;nico, que apresenta uma <i>clearance</i> de creatinina de 25,5 mL/min, dever&#225; ser ponderado o transplante duplo de     f&#237;gado e rim.<sup>20,22-24</sup> Recentemente foi comunicado &#224; MF que a utente     iria iniciar hemodi&#225;lise, situa&#231;&#227;o que ir&#225; manter enquanto aguarda a realiza&#231;&#227;o     do transplante duplo de f&#237;gado e rim para o qual j&#225; foi proposta.</p>       <p>Por tudo o     que foi exposto, pretende-se, com a descri&#231;&#227;o deste caso cl&#237;nico, alertar para     a necessidade de ser sempre realizada investiga&#231;&#227;o de causas secund&#225;rias de     hipertens&#227;o arterial em doentes com este diagn&#243;stico de novo, ou naqueles em     que esta entidade j&#225; &#233; anteriormente conhecida mas que apresentem altera&#231;&#245;es     anal&#237;ticas e/ou imagiol&#243;gicas desajustadas &#224; patologia. A etiologia prim&#225;ria ou     idiop&#225;tica da hipertens&#227;o arterial &#233; a mais frequente mas as causas secund&#225;rias     n&#227;o poder&#227;o ser descuradas, podendo estas, ao serem eliminadas, levar ao     controlo dos valores tensionais. A suspeita diagn&#243;stica e a investiga&#231;&#227;o     dirigida a esta s&#227;o duas situa&#231;&#245;es em que o MF tem um papel fundamental e     privilegiado, tal &#233; a proximidade que tem em rela&#231;&#227;o &#224; comunidade e a     continuidade de cuidados que lhe presta.</p>       ]]></body>
<body><![CDATA[<p>&nbsp;</p>    <p><b>REFER&#202;NCIAS BIBLIOGR&#193;FICAS</b></p>       <!-- ref --><p>1. Roberts     J, Oglesby R. Amyloidosis, Transthyretin-Related. Emedicine [Internet]. Wolf R,     medical editor. Talavera F, pharmacy editor. Brent L, managing editor. Mechaber     A, CME Editor. Besa E, chief editor. 2009 [actualizado em 15/09/2009; acedido     em 04/01/2011]. Dispon&#237;vel em <a href="http://emedicine.medscape.com/article/335301" target="_blank">http://emedicine.medscape.com/article/335301</a>.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000105&pid=S2182-5173201200020000800001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>2. Monteiro     E, Freire A, Barroso E. Familal amyloid polyneuropathy and liver     transplantation. J Hepatol 2004 Aug; 41 (2): 188-194.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000107&pid=S2182-5173201200020000800002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>3. Ando Y,     Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy.     Arch Neurol 2005 Jul; 62 (7): 1057-62.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000109&pid=S2182-5173201200020000800003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>4. Vaz C,     Couto M, Duarte C, Salvador MJ, In&#234;s L, Malcata A. Um caso invulgar de dor     generalizada: paramiloidose simulando fibromialgia. Acta Reumatol Port 2009 Abr-Jun;     34 (2): 431-5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000111&pid=S2182-5173201200020000800004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       ]]></body>
<body><![CDATA[<!-- ref --><p>5. Beir&#227;o I,     Lobato C, Costa PM, Fonseca I, Mendes P, Silva M, et al. Kidney and anemia in     familal amyloidosis type I. Kidney Int 2004 Nov; 66 (5): 2004-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000113&pid=S2182-5173201200020000800005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>6. Rocha A,     Lobato L, Silva H, Beir&#227;o I, Santos J, Pessegueiro H, et al. Characterization     of end-stage renal disease after liver transplantation in transthyretin     amyloidosis (ATTR V30M). Transplant Proc 2011 Jan-Feb; 43 (1): 189-93.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000115&pid=S2182-5173201200020000800006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>7. Lobato L,     Beir&#227;o I, Silva M, Bravo F, Silvestre F, Guimar&#227;es S, et al. Familial ATTR     amyloidosis: microalbuminuria as a predictor of symptomatic disease and     clinical nephropathy. Nephrol Dial Transplant 2003 Mar; 18 (3): 532-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000117&pid=S2182-5173201200020000800007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>8. Carvalho     MJ, Lobato L, Ventura A, Beir&#227;o I, Rocha G, Seca R, et al. Remission of     proteinuria following liver transplantation for familial amyloid polyneuropathy     TTR Met30. Transplant Proc 2000 Dec; 32 (8): 2664-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000119&pid=S2182-5173201200020000800008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>9. Dattilo     P. Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case     report. Cases J 2009 Dec 9; 2: 9295.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000121&pid=S2182-5173201200020000800009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       ]]></body>
<body><![CDATA[<!-- ref --><p>10. Herlenius     G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international experience     with liver transplantation for familial amyloidotic polyneuropathy: results     from the Familial Amyloidotic Polyneuropathy World Transplant Registry.     Transplantation 2004 Jan 15; 77 (1): 64-71.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000123&pid=S2182-5173201200020000800010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>11. Kolstoe     SE, Mangione PP, Belotti V, Taylor GW, Tennent GA, Deroo S, et al. Trapping of     palindromic ligands within native transthyretin prevents amyloid formation.     Proc Natl Acad Sci U S A 2010 Nov 23; 107 (47): 20483-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000125&pid=S2182-5173201200020000800011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>12. Tom&#225;s     MT, Santa-Clara H, Monteiro E, Carolino E, Freire A, Barroso E. Altera&#231;&#245;es da     for&#231;a de preens&#227;o em portadores de polineuropatia amiloid&#243;tica familiar. Acta     Med Port 2010 Set-Out; 23 (5): 803-10.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000127&pid=S2182-5173201200020000800012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>13. Rudolph     T, Kurz MW, Farbu E. Late-onset familial amyloid polyneuropathy (FAP) Val30Met     without family history. Clin Med Res 2008 Sep; 6 (2): 80-2.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000129&pid=S2182-5173201200020000800013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>14. Sekijima     Y, Yoshida K, Tokuda T, Ikeda S. Familial Transthyretin Amyloidosis. National     Center for Biotechnology Information [Internet]. 2001. [actualizado em     15/09/2009; acedido em 04/01/2011]. Dispon&#237;vel em:     <a href="http://www.ncbi.nlm.nih.gov/books/NBK1194" target="_blank">http://www.ncbi.nlm.nih.gov/books/NBK1194</a>.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000131&pid=S2182-5173201200020000800014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       ]]></body>
<body><![CDATA[<!-- ref --><p>15. Ohmori     H, Ando Y, Makita Y, Onouchi Y, Nakajima T, Saraiva MJ, et al. Common origin of     the Val30Met mutation responsible for the amyloidogenic transthyretin type of     familal amyloidotic polyneuropathy. J Med Genet 2004 Apr; 41 (4): e51.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000133&pid=S2182-5173201200020000800015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>16. Mendon&#231;a     T, Pires MM, Reis E, Reis H, Lobato L,Coelho T. Neuropatia perif&#233;rica como     apresenta&#231;&#227;o de amiloidose prim&#225;ria. Sinapse 2005; 5 (2): 90.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000135&pid=S2182-5173201200020000800016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>17. Lobato     L. Familial Amyloidotic Polyneuropathy: how transthyretin associated     amuyloidosis involves the kidney. Port J Nephrol Hypertens 2008 Jan-Mar; 22     (1): 23-30.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000137&pid=S2182-5173201200020000800017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>18. Beir&#227;o     I, Moreira L, Barandela T, Lobato L, Silva P, Gouveia CM, et al. Erythropoietin     production by distal nephron in normal and familial amyloidotic adult human     kidneys. Clin Nephrol 2010 Nov; 74 (5): 327-35.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000139&pid=S2182-5173201200020000800018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>19. Beir&#227;o     I, Lobato L, Moreira L, Costa PM, Fonseca I, Cabrita A, et al. Long-term     treatment of anemia with recombinant human erythropoietin in familial     amyloidosis TTR V30M. Amyloid 2008 Sep; 15 (3): 205-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000141&pid=S2182-5173201200020000800019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       ]]></body>
<body><![CDATA[<!-- ref --><p>20. Beir&#227;o     I, Almeida S, Swinkels D, Costa PM, Moreira L, Fonseca I, et al. Low serum     levels of prohepcidin, but no hepcidin-25, are related to anemia in familial     amyloidosis TTR V30M. Blood Cells Mol Dis 2008 Sep-Oct; 41 (2): 175-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000143&pid=S2182-5173201200020000800020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>21. Lanchman     H, Hawkins P. Amyloidosis, Familial Renal. Emedicine [Internet]. Feinfeld D,     medical editor. Talavera F, pharmacy editor. Aronoff G, managing editor.     Schmidt R, CME editor. Batuman V, chief editor. 2009 [actualizado em     29/10/2009; acedido em 04/01/2011]. Dispon&#237;vel em:     <a href="http://emedicine.medscape.com/article/246221" target="_blank">http://emedicine.medscape.com/article/246221</a>.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000145&pid=S2182-5173201200020000800021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>22. Adams D,     Samuel D, Gloulon-Goeau C, Nakazato M, Costa PM, Feray C et al. The course and     prognostic factors of familial amyloid polyneuropathy after liver     transplantation. Brain 2000 Jul; 123 (Pt 7): 1495-504.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000147&pid=S2182-5173201200020000800022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>23. Lobato     L, Beir&#227;o I, Silva M, Fonseca I, Queir&#243;s J, Rocha G, et al. End-stage disease     and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and     prognostic factors. Amyloid 2004 Mar; 11 (1): 27-37.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000149&pid=S2182-5173201200020000800023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>24. Lobato     L, Ventura A, Beir&#227;o I, Miranda HP, Seca R, Henriques AC, et al. End-stage     renal disease in familial amyloidosis ATTR Val30Met: a definitive indication to     combined liver-kidney transplantation. Transplant Proc 2003 May; 35 (3):     1116-20.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000151&pid=S2182-5173201200020000800024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       ]]></body>
<body><![CDATA[<!-- ref --><p>25. Holmes     Jr R, Baethge B, Edison J. Amyloidosis, Overview. Emedicine [Internet].     Talavera F, pharmacy editor. Brent L, managing editor. Mechaber A, CME Editor.     Diamond H, chief editor. 2009 [actualizado em 30/07/2009; acedido em     04/01/2011]. Dispon&#237;vel em <a href="http://emedicine.medscape.com/article/335414" target="_blank">http://emedicine.medscape.com/article/335414</a>.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000153&pid=S2182-5173201200020000800025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>26. Rakela     J. Recurrencia de la enfermedad hep&#225;tica primaria despu&#233;s del transplante     hep&#225;tico. Rev Med Chile 2010 Abr; 138 (4): 504-10.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000155&pid=S2182-5173201200020000800026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>27. Conselho     Editorial da Revista de Cl&#237;nica Geral. Normas para apresenta&#231;&#227;o de artigos &#224;     Revista Portuguesa de Cl&#237;nica Geral. Rev Port Clin Geral 2010 Mai-Jun; 26 (3):     325-40.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000157&pid=S2182-5173201200020000800027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>28. Empis C.     Por norma ler as normas. Rev Port Clin Geral 2011 Jan-Fev; 27 (1): 11-2.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000159&pid=S2182-5173201200020000800028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <!-- ref --><p>29. Murphy     J, Lloyd M. Hypertension. In: Hogan MJ, editor. Mayo Clinic Cardiology Concise     Textbook. 3rd ed. Rochester, MN: Mayo Clinic Scientific Press; 2007. p.     741-749.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000161&pid=S2182-5173201200020000800029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       ]]></body>
<body><![CDATA[<!-- ref --><p>30. Snanoudj     R, Durrbach A, Gauthier E, Adams D, Samuel D, Ferlicot S, et al. Changes in     renal function in patients with familal amyloid polyneuropathy treated with     orthotopic liver transplantation. Nephrol Dial Transplant 2004 Jul; 19 (7):     1779-85.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000163&pid=S2182-5173201200020000800030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>       <p>&nbsp;</p>    <p><a href="#topc0">Endere&ccedil;o para correspond&ecirc;ncia</a> | <a href="#topc0">Direcci&oacute;n para correspondencia</a> | <a href="#topc0">Correspondence</a><a name="c0"></a></p>       <p>Marta Cristina da Costa Pessoa</p>       <p>Rua de Santo     Ant&#243;nio, 74</p>       <p>3050-456     Pampilhosa</p>       <p><a href="mailto:martacristinapessoa@yahoo.com">martacristinapessoa@yahoo.com</a></p>     <p>&nbsp;</p>       <p><b>CONFLITOS DE INTERESSE</b></p>       ]]></body>
<body><![CDATA[<p>As autoras     declaram n&#227;o ter interesses financeiros, liga&#231;&#245;es pessoais ou outros conflitos     de interesse que possam enviesar o presente trabalho.</p>       <p><b>Recebido em 22/08/2011</b></p>       <p><b>Aceite para publica&#231;&#227;o em 19/03/2012</b></p>      ]]></body>
<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Oglesby]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Talavera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Brent]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mechaber]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Besa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Amyloidosis, Transthyretin-Related]]></source>
<year>2009</year>
<publisher-name><![CDATA[Emedicine]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Freire]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barroso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Familal amyloid polyneuropathy and liver transplantation]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2004</year>
<month>08</month>
<day>00</day>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>188-194</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Araki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Transthyretin-related familial amyloidotic polyneuropathy]]></article-title>
<source><![CDATA[Arch Neurol]]></source>
<year>2005</year>
<month>07</month>
<day>00</day>
<volume>62</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1057-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Couto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Salvador]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Inês]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Malcata]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Um caso invulgar de dor generalizada: paramiloidose simulando fibromialgia]]></article-title>
<source><![CDATA[Acta Reumatol Port]]></source>
<year>2009</year>
<month> A</month>
<day>br</day>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>431-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Kidney and anemia in familal amyloidosis type I]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2004</year>
<month>11</month>
<volume>66</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2004-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pessegueiro]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Characterization of end-stage renal disease after liver transplantation in transthyretin amyloidosis (ATTR V30M)]]></article-title>
<source><![CDATA[Transplant Proc]]></source>
<year>2011</year>
<month> J</month>
<day>an</day>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>189-93</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Silvestre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2003</year>
<month>03</month>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>532-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ventura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Seca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Remission of proteinuria following liver transplantation for familial amyloid polyneuropathy TTR Met30]]></article-title>
<source><![CDATA[Transplant Proc]]></source>
<year>2000</year>
<month>12</month>
<day>00</day>
<volume>32</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2664-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dattilo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case report]]></article-title>
<source><![CDATA[Cases J]]></source>
<year>2009</year>
<month>12</month>
<day>09</day>
<volume>2</volume>
<page-range>9295</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herlenius]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wilczek]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Larsson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ericzon]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry]]></article-title>
<source><![CDATA[Transplantation]]></source>
<year>2004</year>
<month>01</month>
<day>15</day>
<volume>77</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>64-71</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kolstoe]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Mangione]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Belotti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Tennent]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Deroo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Trapping of palindromic ligands within native transthyretin prevents amyloid formation]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2010</year>
<month>11</month>
<day>23</day>
<volume>107</volume>
<numero>47</numero>
<issue>47</issue>
<page-range>20483-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomás]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Santa-Clara]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Carolino]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Freire]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barroso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Alterações da força de preensão em portadores de polineuropatia amiloidótica familiar]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2010</year>
<month> S</month>
<day>et</day>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>803-10</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rudolph]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kurz]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Farbu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Late-onset familial amyloid polyneuropathy (FAP) Val30Met without family history]]></article-title>
<source><![CDATA[Clin Med Res]]></source>
<year>2008</year>
<month>09</month>
<day>00</day>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>80-2</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sekijima]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tokuda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ikeda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Familial Transthyretin Amyloidosis]]></source>
<year>2001</year>
<publisher-name><![CDATA[National Center for Biotechnology Information]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohmori]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Makita]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Onouchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nakajima]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Saraiva]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familal amyloidotic polyneuropathy]]></article-title>
<source><![CDATA[J Med Genet]]></source>
<year>2004</year>
<month>04</month>
<day>00</day>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e51</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendonça]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pires]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Reis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Reis]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Neuropatia periférica como apresentação de amiloidose primária]]></article-title>
<source><![CDATA[Sinapse]]></source>
<year>2005</year>
<month>00</month>
<day>00</day>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>90</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Familial Amyloidotic Polyneuropathy: how transthyretin associated amuyloidosis involves the kidney]]></article-title>
<source><![CDATA[Port J Nephrol Hypertens]]></source>
<year>2008</year>
<month> J</month>
<day>an</day>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-30</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Barandela]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gouveia]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin production by distal nephron in normal and familial amyloidotic adult human kidneys]]></article-title>
<source><![CDATA[Clin Nephrol]]></source>
<year>2010</year>
<month>11</month>
<day>00</day>
<volume>74</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>327-35</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrita]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Long-term treatment of anemia with recombinant human erythropoietin in familial amyloidosis TTR V30M]]></article-title>
<source><![CDATA[Amyloid]]></source>
<year>2008</year>
<month>09</month>
<day>00</day>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>205-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Swinkels]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Low serum levels of prohepcidin, but no hepcidin-25, are related to anemia in familial amyloidosis TTR V30M]]></article-title>
<source><![CDATA[Blood Cells Mol Dis]]></source>
<year>2008</year>
<month> S</month>
<day>ep</day>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>175-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lanchman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hawkins]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Feinfeld]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Talavera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Aronoff]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Batuman]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Amyloidosis, Familial Renal]]></source>
<year>2009</year>
<publisher-name><![CDATA[Emedicine]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Samuel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gloulon-Goeau]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nakazato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Feray]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2000</year>
<month>07</month>
<day>00</day>
<volume>123</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1495-504</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Queirós]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[End-stage disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors]]></article-title>
<source><![CDATA[Amyloid]]></source>
<year>2004</year>
<month>03</month>
<day>00</day>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-37</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lobato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ventura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beirão]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Seca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Henriques]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[End-stage renal disease in familial amyloidosis ATTR Val30Met: a definitive indication to combined liver-kidney transplantation]]></article-title>
<source><![CDATA[Transplant Proc]]></source>
<year>2003</year>
<month>05</month>
<day>00</day>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1116-20</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holmes Jr]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Baethge]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Edison]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Talavera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Brent]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mechaber]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Diamond]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Amyloidosis, Overview]]></source>
<year>2009</year>
<publisher-name><![CDATA[Emedicine]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rakela]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Recurrencia de la enfermedad hepática primaria después del transplante hepático]]></article-title>
<source><![CDATA[Rev Med Chile]]></source>
<year>2010</year>
<month>04</month>
<volume>138</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>504-10</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<collab>Conselho Editorial da Revista de Clínica Geral</collab>
<article-title xml:lang="pt"><![CDATA[Normas para apresentação de artigos à Revista Portuguesa de Clínica Geral]]></article-title>
<source><![CDATA[Rev Port Clin Geral]]></source>
<year>2010</year>
<month> M</month>
<day>ai</day>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>325-40</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Empis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Por norma ler as normas]]></article-title>
<source><![CDATA[Rev Port Clin Geral]]></source>
<year>2011</year>
<month> J</month>
<day>an</day>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-2</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hypertension]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Hogan]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Mayo Clinic Cardiology Concise Textbook]]></source>
<year>2007</year>
<month>00</month>
<day>00</day>
<edition>3</edition>
<page-range>741-749</page-range><publisher-loc><![CDATA[Rochester^eMN MN]]></publisher-loc>
<publisher-name><![CDATA[Mayo Clinic Scientific Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Snanoudj]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Durrbach]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gauthier]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Samuel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlicot]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Changes in renal function in patients with familal amyloid polyneuropathy treated with orthotopic liver transplantation]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2004</year>
<month>07</month>
<volume>19</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1779-85</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
